Current insights suggest that the m6A methylome in cancer cells is predominantly influenced by the post-translational modification of proteins associated with m6A. These modifications either modulate the catalytic activities of m6A methyltransferases and demethylases or impact the ability of m6A reader proteins to interact with and process m6A-modified mRNA. The gene discussed is MBD2; the disease is cancer.